- Home
- BPMC
as 03-28-2025 4:00pm EST
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 5.8B | IPO Year: | 2015 |
| Target Price: | $124.29 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 22 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $80.68 - $121.90 | Next Earning Date: | 05-01-2025 |
| Revenue: | $508,824,000 | Revenue Growth: | 104.04% |
| Revenue Growth (this year): | 45.43% | Revenue Growth (next year): | 32.80% |
Stock Insider Trading Activity of Blueprint Medicines Corporation (BPMC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rossi Christina | BPMC | CHIEF OPERATING OFFICER | Mar 24 '25 | Sell | $95.02 | 2,274 | $216,075.48 | 69,266 | |
| Albers Jeffrey W. | BPMC | Director | Mar 12 '25 | Sell | $88.00 | 7,500 | $658,500.00 | 154,196 | |
| Albers Jeffrey W. | BPMC | Director | Mar 5 '25 | Sell | $88.80 | 5,766 | $512,020.80 | 154,196 | |
| Landsittel Michael | BPMC | CHIEF FINANCIAL OFFICER | Mar 5 '25 | Sell | $88.80 | 5,284 | $469,219.20 | 72,924 | |
| Lee Philina | BPMC | CHIEF COMMERCIAL OFFICER | Mar 5 '25 | Sell | $88.80 | 3,733 | $331,490.40 | 41,996 | |
| Durso-Bumpus Debra | BPMC | CHIEF PEOPLE OFFICER | Mar 5 '25 | Sell | $88.80 | 5,157 | $457,941.60 | 49,606 | |
| Rossi Christina | BPMC | CHIEF OPERATING OFFICER | Mar 5 '25 | Sell | $88.80 | 6,495 | $576,756.00 | 69,266 | |
| Namouni Fouad | BPMC | PRESIDENT, R & D | Mar 5 '25 | Sell | $88.80 | 6,489 | $576,223.20 | 75,781 | |
| Hurley Ariel | BPMC | PRINCIPAL ACCOUNTING OFFICER | Mar 5 '25 | Sell | $88.80 | 1,326 | $117,748.80 | 16,944 | |
| McCain Tracey L | BPMC | EVP AND CHIEF LEGAL OFFICER | Mar 5 '25 | Sell | $88.80 | 5,262 | $467,265.60 | 66,583 |
Latest Blueprint Medicines Corporation News
BPMC Breaking Stock News: Dive into BPMC Ticker-Specific Updates for Smart Investing
Insider Monkey
3 days ago
Is Blueprint Medicines Corporation (BPMC) a Promising Biotech Stock According to Wall Street Analysts
Insider Monkey
9 days ago
Blueprint Medicines (BPMC): Among Stocks Insiders Are Selling In March
TipRanks
11 days ago
Reddit initiated, Netflix upgraded: Wall Street’s top analyst calls
MT Newswires
11 days ago
Wolfe Research Initiates Blueprint Medicines at Outperform With $132 Price Target
Simply Wall St.
16 days ago
Exploring High Growth Tech Stocks In The US Market March 2025
MT Newswires
22 days ago
Blueprint Medicines Insider Sold Shares Worth $467,266, According to a Recent SEC Filing
MT Newswires
22 days ago
Blueprint Medicines Insider Sold Shares Worth $576,223, According to a Recent SEC Filing
MT Newswires
22 days ago
Blueprint Medicines Insider Sold Shares Worth $576,756, According to a Recent SEC Filing
Compare BPMC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BPMC Blueprint Medicines Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.